Try a new search

Format these results:

Searched for:

in-biosketch:yes

person:laskae01

Total Results:

189


"THE ANALGESIC EFFICACY, OF IBUPROFEN, CODEINE AND PLACEBO" [Meeting Abstract]

Sunshine, A; Roure, C; Zorrilla, C; Laska, E; Olson, N; Rivera, J
ISI:A1985ACH9800229
ISSN: 0009-9236
CID: 30980

Caffeine as an analgesic adjuvant

Laska EM; Sunshine A; Mueller F; Elvers WB; Siegel C; Rubin A
Thirty clinical studies involving more than 10,000 patients conducted during the last 20 years have been analyzed to assess the value of caffeine as an analgesic adjuvant. Although most studies included patients with postpartum uterine cramping or episiotomy pain, some involved patients with pain from oral surgery or headache. In 21 of 26 studies, the relative potency estimates of an analgesic with caffeine to an analgesic without caffeine is greater than one. The pooled relative potency estimates in each of several major categories of combination analgesics are significantly greater than one. The overall pooled relative potency estimate is 1.41, with 95% confidence limits of 1.23 to 1.63; that is, to obtain the same amount of response from an analgesic without caffeine requires a dose that is approximately 40% greater than one with caffeine.
PMID: 6366275
ISSN: 0098-7484
CID: 10146

Analgesic efficacy of intramuscular flunixin meglumine compared to meperidine: a preliminary report

Sunshine A; Zighelboim I; Olson N; De Castro A; Laska E
PMID: 6085767
ISSN: 1046-9516
CID: 10147

Optimal crossover designs in the presence of carryover effects

Laska, E; Meisner, M; Kushner, H B
Under either the random patient-effect model with sequence effects or the fixed patient-effect model, the usual two-period, two-treatment crossover design, AB,BA, cannot be used to estimate the contrast between direct treatment effects when unequal carryover effects are present. If baseline observations are available, the design AB,BA can validly be used to estimate a treatment contrast. However, the design AB,BA,AA,BB with baseline observations is more efficient. In fact, we show that this design is optimal whether or not baseline observations are available. For experiments with more than two periods, universally optimal designs are found for both models, with and without carryover effects. It is shown that uncertainty about the presence of carryover effects is of little or no consequence, and the addition of baseline observations is of little or no added value for designs with three or more periods; however, if the experiment is limited to only two periods the investigator pays a heavy penalty
PMID: 6671121
ISSN: 0006-341x
CID: 140514

Analgesic effects of oral propiram fumarate, codeine sulfate and placebo in postoperative pain

Sunshine A; Laska EM; Olson NZ; Colon A; Gonzalez L; Tirado S
Our purpose was to evaluate the analgesic efficacy and safety of single oral doses of propiram fumarate 50 mg, codeine sulfate 60 mg and placebo in the relief of moderate to severe postoperative pain. One hundred and twenty patients completed a randomized, double-blind, single-dose, stratified, parallel-groups trial and were observed for either 4 or 6 hours. Based upon each of the summary efficacy measures--SPID, % SPID and TOTAL--propiram and codeine were approximately equally effective and both were statistically superior to placebo. Propiram was significantly more effective than codeine at hour 5 for Pain Intensity Difference. Two adverse effects were attributed to propiram. Propiram fumarate 50 mg is an effective oral analgesic similar to codeine sulfate 60 mg, with the possibility of a longer duration of action
PMID: 6359083
ISSN: 0277-0008
CID: 10148

Ibuprofen, zomepirac, aspirin, and placebo in the relief of postepisiotomy pain

Sunshine A; Olson NZ; Laska EM; Zighelboim I; De Castro A; De Sarrazin C
Our purpose was to compare the analgesic efficacy of single oral doses of ibuprofen, zomepirac, aspirin, and placebo in severe postepisiotomy pain. One hundred twenty subjects participated in a double-blind, single-dose, parallel-group, 4-hr trial comparing 400 mg ibuprofen, 100 mg zomepirac sodium, 600 mg aspirin, and placebo. For most parameters, including the sum of the pain intensity differences (SPID) and the sum of the hourly pain relief values (TOTAL), which are summary variables, each of the drugs was more effective than placebo. Ibuprofen was more effective than aspirin and zomepirac. Zomepirac and aspirin were equally effective for most of the analgesic variables. There were no adverse effects. Ibuprofen, 400 mg, is an effective oral analgesic and is more effective than 100 mg zomepirac and 600 mg aspirin in most parameters of pain
PMID: 6872421
ISSN: 0009-9236
CID: 10149

Deinstitutionalization and the survival of the state hospital

Craig TJ; Laska EM
Despite vigorous efforts at deinstitutionalization, the state mental hospital continues to be the locus of care for a wide variety of patient populations. The authors examined the changes in one state hospital's clientele between 1972 and 1980 and discovered a 50 percent reduction in long-stay patients, a 27 percent increase in admissions, and the emergence of a new long-stay population. The authors say that the modern state hospital can be conceptualized as several different facilities under a single administrative roof rather than as a monolithic structure. They conclude that mental health planners must acknowledge the continued existence of a group of patients whose needs are perhaps best served by the state hospital. Strategies must be developed to use the existing hospital resources in the most efficient and effective manner
PMID: 6411582
ISSN: 0022-1597
CID: 60350

Analgesic effect of graded doses of flurbiprofen in post-episiotomy pain

Sunshine A; Olson NZ; Laska EM; Zighelboim I; De Castro A; De Sarrazin C
Our purpose was to evaluate the analgesic efficacy and safety of single oral doses of flurbiprofen 25, 50 and 100 mg, aspirin 600 mg, and placebo in the relief of moderate to severe post-episiotomy pain. One hundred and fifty-two evaluable patients completed a randomized, double-blind, stratified, parallel groups study. They were observed over a six hour period by one nurse-observer. Based upon each of the summary efficacy measures SPID, TOTAL and PEAK % and most of the hourly direct measures of pain intensity and pain relief, each of the four active treatments were statistically superior to placebo. Flurbiprofen 25 mg appeared to be slightly less effective than aspirin 600 mg, but the differences were not statistically significant. Flurbiprofen 50 and 100 mg were quite similar and were significantly more effective than aspirin 600 mg and flurbiprofen 25 mg. There were no observed or reported adverse effects
PMID: 6348714
ISSN: 0277-0008
CID: 10150

Effect of caffeine on acetaminophen analgesia

Laska EM; Sunshine A; Zighelboim I; Roure C; Marrero I; Wanderling J; Olson N
Our objective was to determine the value of caffeine in combination with acetaminophen in the relief of pain from uterine cramping, episiotomy, and third molar extraction. In the dental study, 173 patients received two or four tablets of 500 mg acetaminophen or the combination of 500 mg acetaminophen and 65 mg caffeine. In the three postpartum studies, 1345 patients received one, two, or three tablets of acetaminophen, the combination, or a placebo. The mean scores for the summary variable percent sum of the pain intensity differences (% SPID) were higher in all for the combination than for acetaminophen alone, and in two studies the null hypothesis of no differences was rejected. The relative potency estimates for % SPID were 1.9, 1.8, and 1.3 for the three studies in which bioassays could be performed and the pooled relative potency was 1.7 with a 95% confidence interval of 1.1 to 3.1. The results were essentially the same among pain models and among patient groups with similar habitual caffeine consumption. Onset of analgesia was also faster with the combination. We conclude that caffeine enhances the analgesic efficacy of acetaminophen
PMID: 6831829
ISSN: 0009-9236
CID: 10151

A STUDY OF THE ANALGESIC EFFICACY OF NALBUPHINE HYDROCHLORIDE IN PATIENTS WITH POSTPARTUM PAIN

Sunshine, A; Zighelboim, I; Desarrazin, C; Decastro, A; Olson, NZ; Laska, E
ISI:A1983PZ68200016
ISSN: 0011-393x
CID: 30681